5 February 2025 - Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.

Elacestrant is recommended as an option for treating oestrogen receptor (ER)-positive HER2-negative locally advanced or metastatic breast cancer with an activating ESR1 mutation that has progressed after at least 1 line of endocrine treatment plus a cyclin-dependent kinase (CDK) 4 and 6 inhibitor in:

women, trans men and non-binary people who have been through the menopause

trans women and men.

Elacestrant is recommended only if:

the cancer has progressed after at least 12 months of endocrine treatment plus a CDK 4 and 6 inhibitor, and

the company provides it according to the commercial arrangement.

Read NICE technology appraisal guidance